Publications

255 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

Periode

Enter a start and/or end date here, using the following format: DD-MM-YYYY.

You can select a specific type of a publication you are looking for, such as press releases or speeches

Brexpiprazole (Rxulti®) for the treatment of schizophrenia in adults

Zorginstituut Nederland carried out a marginal assessment whether the product brexpiprazole (Rxulti®) can be accepted into the ...

Report | 16-04-2019

Pitolisant (Wakix®) for the treatment of narcolepsy in adults

Zorginstituut Nederland carried out a marginal assessment whether pitolisant (Wakix®) is interchangeable with a drug currently ...

Report | 15-04-2019

Glycopyrronium bromide (Sialanar®) for the symptomatic treatment of severe sialorrhoea

Zorginstituut Nederland carried out an assessment whether the product glycopyrronium bromide (Sialanar®) is interchangeable with ...

Report | 09-04-2019

Tolvaptan (Jinarc ®) for the treatment of chronic kidney disease - alteration of the specific conditions

Zorginstituut Nederland carried out an assessment whether the specific conditions for tolvaptan (Jinarc ®) can be altered. ...

Report | 02-04-2019

Durvalumab (Imfinzi®) for the treatment of locally advanced, unresectable, non-small cell lung cancer

Zorginstituut Nederland has completed its assessment of durvalumab (Imfinzi®) as monotherapy for the treatment of locally ...

Report | 01-04-2019

Organisation structure National Health Care Institute

Publication | 26-03-2019

Amendment of the conditional inclusion of the medicine Fingolimod (Gilenya®) for the treatment of relapsing remitting multiple sclerosis (RRMS)

Zorginstituut Nederland carried out an assessment in relation to extending the specific conditions for the medicinal  product ...

Report | 25-03-2019

Abemaciclib (Verzenios®) for the treatment of metastatic breast cancer

Zorginstituut Nederland has completed its assessment of abemaciclib (Verzenios®) for the treatment of metastatic breast cancer. ...

Report | 07-03-2019

Axicabtagene ciloleucel (Yescarta®) for the treatment of adult patients with recurring or refractory diffuse large-cell B-cell lymphoma (DLBCL) and primary mediastinal large-cell B-cell lymphoma (PMBCL)

Zorginstituut Nederland carried out an assessment of the medicinal product axicabtagene ciloleucel (axi-cel, Yescarta®) for the ...

Report | 07-03-2019

Tisagenlecleucel (Kymriah®) for the treatment of DLBCL

Zorginstituut Nederland has completed its assessment of tisagenlecleucel (Kymriah®) for the treatment of DLBCL. Due to its ...

Report | 07-03-2019